Antiplatelet drug resistance: Not ready for prime time

Pharmacotherapy

Volumn 25, Issue 11 I, 2005, Pages 1621-1628

  Burns, Tammy L ^a   Mooss, Aryan N ^a   Hilleman, Daniel E ^a  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Antiplatelet drugs; Antiplatelet therapy; Platelet function; Resistance; Vascular adverse events

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; CREATINE KINASE MB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBOXANE A2; TICLOPIDINE; TROPONIN I; WARFARIN;

AGGREGOMETER; ANALYZER; BLEEDING; BLEEDING TIME; BLOOD LEVEL; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG INDICATION; HEART INFARCTION; HEMATOLOGICAL PARAMETERS; HUMAN; LABORATORY TEST; MEDICAL INSTRUMENTATION; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; SERUM; SHORT SURVEY; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; URINARY EXCRETION;

BLOOD PLATELETS; CLINICAL TRIALS; CORONARY DISEASE; DRUG RESISTANCE; HUMANS; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS;

EID: 27644559048     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11.1621     Document Type: Short Survey

References (46)

1. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
2. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961-5.
3. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by the PFA-100 in patients with coronary artery disease. Thromb Res 2003;108:37-42.
4. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet activity. Circulation 2003;107:2908-13.
6. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43(6):1122-6.
7. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicemer study. Circulation 2001;103:2572-8.
8. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-6.
9. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and non-responder: a pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
10. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-7.
11. Michelson AD. Platelet function testing in cardiovascular diseases [online exclusive article]. Circulation 2004;110:e489-93. Available from http://circ.ahajournals.org/ cgi/content/full/110/19/e489.
12. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002;13:37-40.
13. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
14. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003;110:281-6.
15. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance [letter]. Lancet 1999;353:900.
16. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-7.
17. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003;73:122-30
18. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet P1A1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ib-alpha) polymorphisms. J Am Coll Cardiol 2003;42:1115-9.
19. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. P1(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666-72.
20. Pontiggia L, Lassila R, Pederiva S, Schmid HR, Burger M, Beer JH. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GP Ia and GP IIIa. Arterioscler Thromb Vasc Biol 2002;22:2093-8.
21. Quinn MJ, Topol EJ. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2001;2:341-52.
22. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-71.
23. Jack DB. One hundred years of aspirin. Lancet 1997;350:437-9.
24. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
25. Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2004;126:2345-64.
26. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
27. Fitzgerald GA. Ticlopidine in unstable angina: a more expensive aspirin? Circulation 1990;82:296-8.
28. Yeh SP, Hsueh EJ, Wu H, et al. Ticlopidine-associated aplastic anemia: a case report and review of the literature. Ann Hematol 1998;76:87-90.
29. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
30. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502.
31. [Errata in N Engl J Med 2001;345(23):1716,
32. N Engl J Med 2001;345(20):1506.]
33. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
34. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-13.
35. Helgason CM, Hoff JA, Kondos GT, Brace LD. Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke 1993;24:1458-91.
36. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-50.
37. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
38. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004;43(6):1127-9.
39. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-7.
40. Dade-Behring. PFA-100 product information. Available from www.plateletperspectives.com. Accessed December 21, 2004.
41. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
42. Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001;141:226-33.
43. Accumetrics. VerifyNow product information. Available from www.accumetrics.com. Accessed February 22, 2005.
44. Hurlen M, Abdelnoor M, Smith P, Eriksen J, Arnesen H. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002;347:969-74.
45. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
46. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.